Ticker brief
IONS
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
15
authors 14d
9
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-02 · now +0.00 (−1 bearish … +1 bullish)
Who spoke9
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @alphaticaio | B | +0.34 | 4 | +0.54 |
| @BPharmCatalyst | C | · | 2 | +0.00 |
| @OzmosiHealth | C | · | 2 | +0.40 |
| @Quantumup1 | C | -1.95 | 2 | +0.30 |
| @semodough | C | -0.75 | 1 | +0.00 |
| @FierceBiotech | A | -0.09 | 1 | +0.35 |
| @OptionsFlowBoss | C | · | 1 | +0.35 |
| @BiopharmIQ | B | · | 1 | +0.50 |
| @kiantrades | C | -3.34 | 1 | +0.20 |
Recent signals15of 15 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @Quantumup1 | +0.00 | H.C. Wainwright reiterated ARWR Buy with $100 PT after cardiometabolic R&D webinar. | · | tweet ↗ |
| 2026-06-29 | @kiantrades | +0.20 | Lists notable call flow with strikes, expiries, and premiums. | · | tweet ↗ |
| 2026-06-29 | @alphaticaio | +0.70 | Updated quadrant call cites confirmed bullish regime and broken $79 ceiling. | · | tweet ↗ |
| 2026-06-29 | @BiopharmIQ | +0.50 | FDA recap: IONS and VRDN approvals; LNTH CRL due to manufacturing facility issues. | · | tweet ↗ |
| 2026-06-26 | @alphaticaio | +0.55 | Suggests someone is positioning for a buyout in IONS. | · | tweet ↗ |
| 2026-06-26 | @alphaticaio | +0.55 | Notes IONS up another 4% and says something cooking. | · | tweet ↗ |
| 2026-06-25 | @alphaticaio | +0.35 | Notes aggressive August 80 call adds and three price hikes in IONS. | · | tweet ↗ |
| 2026-06-25 | @OptionsFlowBoss | +0.35 | Lists unusual bullish options volume near close; capped to first six tickers. | · | tweet ↗ |
| 2026-06-25 | @Quantumup1 | +0.60 | Needham reiterated IONS Buy; H.C. Wainwright raised PT to $130 after FDA approval. | · | tweet ↗ |
| 2026-06-25 | @FierceBiotech | +0.35 | Ionis gets $30M from Recordati for ex-US rights to rare disease prospect. | · | tweet ↗ |
| 2026-06-25 | @OzmosiHealth | +0.30 | Ionis announces license agreement with Recordati for zilganersen outside the U.S. | · | tweet ↗ |
| 2026-06-24 | @OzmosiHealth | +0.50 | FDA approves TRYNGOLZA for severe hypertriglyceridemia treatment indication. | · | tweet ↗ |
| 2026-06-22 | @semodough | +0.00 | RBC KOL left author incrementally more positive on RARE ahead of pivotal data, but notes 50/50 Phase III risk. | · | tweet ↗ |
| 2026-06-19 | @BPharmCatalyst | +0.00 | Biotech watchlist calendar names tickers but gives no stance. | · | tweet ↗ |
| 2026-06-19 | @BPharmCatalyst | +0.00 | Weekly biotech watchlist lists tickers without specific stance. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.